On December 15, 2005, Weller, Thomas; Koberstein, Ralf; Aissaoui, Hamed; Clozel, Martine; Fischli, Walter published a patent.Name: (S)-2-Hydroxy-N-methyl-2-phenylacetamide The title of the patent was Preparation of substituted 1,2,3,4-tetrahydroisoquinolines as orexin receptor antagonists. And the patent contained the following:
Title compounds I [R1-2 = H, alkoxy; R3 = alkyl; X = CH, N] are prepared For instance, II is prepared from a Ru-catalyzed enantioselective alkylation of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline with 1-bromomethyl-4-trifluoromethylbenzene followed by alkylation of the resulting isoquinoline with (S)-α-(4-toluenesulfonyloxy)-N-methylphenylacetamide (preparation given). Compounds of the invention are orexin antagonists with activity in the nanomolar range. I are useful for the treatment of, e.g., anxiety and depression. The experimental process involved the reaction of (S)-2-Hydroxy-N-methyl-2-phenylacetamide(cas: 65645-88-7).Name: (S)-2-Hydroxy-N-methyl-2-phenylacetamide
The Article related to tetrahydroisoquinoline orexin receptor antagonist process preparation, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Name: (S)-2-Hydroxy-N-methyl-2-phenylacetamide
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics